Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Mepolizumab 

Brand: Nucala ®
NICE TA: 431
Indication: Mepolizumab for treating severe refractory eosinophilic asthma (NICE TA431)
Disease category: Respiratory system
Commissioning responsibility: NHSE
PbR excluded: Yes

Background

Mepolizumab, as an add-on to optimised standard therapy, is recommended as an option for treating severe refractory eosinophilic asthma in adults, only if: •the blood eosinophil count is 300 cells/microlitre or more in the previous 12 months and •the person has agreed to and followed the optimised standard treatment plan and •has had 4 or more asthma exacerbations needing systemic corticosteroids in the previous 12 months or •has had continuous oral corticosteroids of at least the equivalent of prednisolone 5 mg per day over the previous 6 months and •the company provides the drug with the discount agreed in the patient access scheme.

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA431 - Mepolizumab for treating severe refractory eosinophilic asthma

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red